Curriculum Vitaes
Profile Information
- Affiliation
- School of Medicine, Fujita Health University
- Degree
- 博士(医学)(名古屋大学)
- J-GLOBAL ID
- 200901048638344557
- researchmap Member ID
- 5000024641
- External link
Education:
1993 Ph.D. (Dr of Medical Science) Nagoya University The Graduate School of Medicine
(Prof. Toshiharu Nagatsu)
1989 M.D. Nagoya University School of Medicine
Professional training:
2017-present Vice president, Fujita Health University
2015-present Dean of the School of Medicine, Fujita Health University
2003-present Professor, Dep. Psychiatry, Fujita Health University School of Medicine
2002-2003 Assoc. Prof. Dep. Psychiatry, Fujita Health University School of Medicine
1998-2002 Assit. Prof. Dep. Psychiatry, Fujita Health University School of Medicine
(Prof. Norio Ozaki)
1996-1998 Visiting Fellow, Lab. Neurogenetics, NIAAA/NIH
(Dr. David Goldman)
1994-1996 Medical Staff, Dep. Psychiatry, Nagoya University School of Medicine
(Prof. Tatsuro Ohta)
1993-1994 Clinical Fellow in Medicine, North Hospital, Nagoya
1989-1990 Resident in Medicine, Kyoritsu General Hospital, Nagoya
Research field
Psychiatric genetics, Pharmacogenetics, Clinical psychopharmacology
NAKAO IWATA, M.D., Ph.D. is Professor of Psychiatry Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, JAPAN. He attended medical school and graduate school at Nagoya University and majored molecular neurochemistry and clinical psychiatry. He has published on many topics, including psychiatric genetics, pharmacogenomics, and clinical neuropsychopharmacology.
1993 Ph.D. (Dr of Medical Science) Nagoya University The Graduate School of Medicine
(Prof. Toshiharu Nagatsu)
1989 M.D. Nagoya University School of Medicine
Professional training:
2017-present Vice president, Fujita Health University
2015-present Dean of the School of Medicine, Fujita Health University
2003-present Professor, Dep. Psychiatry, Fujita Health University School of Medicine
2002-2003 Assoc. Prof. Dep. Psychiatry, Fujita Health University School of Medicine
1998-2002 Assit. Prof. Dep. Psychiatry, Fujita Health University School of Medicine
(Prof. Norio Ozaki)
1996-1998 Visiting Fellow, Lab. Neurogenetics, NIAAA/NIH
(Dr. David Goldman)
1994-1996 Medical Staff, Dep. Psychiatry, Nagoya University School of Medicine
(Prof. Tatsuro Ohta)
1993-1994 Clinical Fellow in Medicine, North Hospital, Nagoya
1989-1990 Resident in Medicine, Kyoritsu General Hospital, Nagoya
Research field
Psychiatric genetics, Pharmacogenetics, Clinical psychopharmacology
NAKAO IWATA, M.D., Ph.D. is Professor of Psychiatry Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, JAPAN. He attended medical school and graduate school at Nagoya University and majored molecular neurochemistry and clinical psychiatry. He has published on many topics, including psychiatric genetics, pharmacogenomics, and clinical neuropsychopharmacology.
Research Areas
1Research History
5Education
2-
1983 - 1989
Papers
659-
Psychiatry and clinical neurosciences, Feb 10, 2026AIM: This network meta-analysis of randomized controlled trials (RCTs) aimed to investigate which hypnotics are associated with the most favorable sleep architecture and respiratory outcomes in adults with obstructive sleep apnea. METHODS: Primary outcomes included total sleep time (TST) and apnea-hypopnea index (AHI) during TST. Other outcomes were rapid eye movement (REM) sleep time, latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), AHI during non-REM or REM sleep, mean peripheral oxygen saturation (SpO2) during TST, mean SpO2 nadir during TST, arousal index (AI), all-cause discontinuation, adverse event-related discontinuation, and incidence of individual adverse events. Effect sizes with 95% confidence intervals were calculated. RESULTS: This systematic review included 32 RCTs (n = 1871, average age = 51.60 years, 62.52% male, mean AHI = 23.60). Our network meta-analysis evaluated brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, zopiclone, and placebo. Compared with placebo, lemborexant increased TST, REM sleep time, and SE and decreased LPS and WASO, whereas both daridorexant and zolpidem increased TST and SE and decreased WASO. These three medications demonstrated respiratory safety and discontinuation profiles similar to those of placebo. Eszopiclone increased TST and SE and decreased LPS, WASO, AHI during TST, and AI, but its effects on LPS, WASO, AHI during TST, and AI disappeared in the sensitivity analysis, excluding continuous positive airway pressure titration studies. CONCLUSION: Our network meta-analysis identified different effects of various hypnotics on sleep architecture and respiratory parameters; however, the lack of data prevented a formal synthesis of subjective outcomes. Therefore, these results should be interpreted with caution in clinical practice.
-
Schizophrenia research. Cognition, 42 100390-100390, Dec, 2025BACKGROUND: Cognitive dysfunction has a significant impact on social functioning, such as employment, in patients with schizophrenia. However, existing cognitive assessments are time-consuming, impose a significant burden on patients, and require specialized training for evaluators, making them impractical for routine clinical use. Therefore, the present study investigated whether a simple and novel assessment tool, called Psychomotor Function Tests (PFT), correlates with existing Neuropsychological Tests (NT) and assessments with the Life Assessment Scale for the Mentally Ill (LASMI), which evaluates social functioning, including employment. METHODS: Cognitive function was examined in 24 patients with schizophrenia using NT (the Japanese Adult Reading Test, Trail Making Test (TMT), and word fluency test) and tablet-based PFT, while social functioning was evaluated using LASMI. Twenty-four healthy controls (HCs) underwent the same cognitive assessments. RESULTS: Psychomotor function, as evaluated by the choice reaction time, compensatory tracking test, and rapid visual information processing, was significantly worse in patients with schizophrenia than in HCs (p < 0.001). Furthermore, the composite score of PFT correlated with the time required for TMT (r = -0.707, -0.637) and LASMI subscales related to work, endurance & stability, self-recognition, required skills, and retention skills (r = -0.640, -0.689, -0.634, -0.420, -0.548). CONCLUSION: PFT correlated with existing NT, which are widely used in cognitive function assessments. Cognitive function examined by PFT was closely associated with social functioning. These results suggest the potential of PFT for evaluating cognitive function in routine clinical settings for patients with schizophrenia.
-
Molecular psychiatry, Nov 5, 2025Sensory issues are common in autism spectrum disorders (ASD) and can significantly affect daily living. The phenomena of gating and habituation of event-related potentials (ERPs) to repetitive stimuli have been suggested as potential biomarkers reflecting atypical sensory processing in ASD. Sensory hypersensitivity and anxiety are closely related in ASD, and habituation to emotionally evocative stimuli may serve as a more sensitive biomarker for sensory hypersensitivity symptoms. However, previous studies have primarily used tonal stimuli, and there has been little investigation into whether habituation to emotionally evocative sounds is impaired in ASD patients. In this study, we compared the degree of habituation of the P1-N1 peak-to-peak amplitude in response to repeated tones and fearful vocalizations between control and ASD groups. Contrary to expectations, no significant difference was observed for fearful vocalizations between the groups, while ASD patients showed significantly reduced habituation to tonal sounds in the left parieto-occipital region. Furthermore, we found a significant correlation between the degree of habituation to tonal sounds in the left parieto-occipital region and sensory hypersensitivity symptoms in ASD patients, and similar abnormalities in BTBR mice, an animal model of ASD. These results suggest that habituation to tonal sounds, rather than emotionally evocative stimuli, may serve as a translational biomarker reflecting sensory hypersensitivity symptoms.
-
Neuropsychopharmacology Reports, 45(3), Sep 4, 2025ABSTRACT Objective To examine the characteristics associated with happiness in Japanese individuals with schizophrenia. Methods A self‐reported online survey was conducted in 2022 among individuals aged 20–75 years, including 223 and 1776 individuals with and without schizophrenia, respectively. We used a modified Poisson regression to assess the factors associated with happiness by calculating the age‐ and sex‐adjusted prevalence ratios (PRs). We examined within‐schizophrenia group differences by age and sex strata, and compared these stratified PRs between groups with and without schizophrenia. Results Among participants with schizophrenia, happiness was significantly associated with self‐rated health status (PR = 1.75), Ikigai (PR = 5.02), depressive symptoms (PR = 0.43), perceived stress (PR = 0.52), cognitive social capital (PR = 2.07), structural social capital (PR = 1.70), social support (PR = 2.40), close friends (PR = 1.88), close relatives (PR = 2.34), and a cohabiting partner (PR = 1.57). Within the schizophrenia group, sex differences were significant for cognitive social capital (men: PR = 3.45; women: PR = 1.43) and cohabiting partners (men: PR = 2.26; women: PR = 1.25), whereas no significant age differences were found. Factors demonstrating a stronger association in participants with schizophrenia than in those without schizophrenia included: Ikigai (with, PR = 5.02; without, PR = 2.91), cognitive social capital (with, PR = 2.07; without, PR = 1.49), and structural social capital (with, PR = 1.70; without, PR = 1.24). Conclusion Happiness in individuals with schizophrenia is associated with physical, mental, and social factors, with social factors exhibiting sex‐related differences.
Misc.
650-
臨床精神薬理, 10(5) 825-830, May, 2007
-
Bipolar Disorder, 5 95-101, May, 2007
-
精神薬療研究年報, (39) 133-138, Mar, 2007視床下部-脳下垂体-副腎系(HPA-axis関連遺伝子群のうち、Glucocorticoid receptor gene(NR3C1)、FKBP5(glucocorticoid receptor-regulating cochaperone of hsp-90)、Angiotensin-converting enzyme(ACE)、GABAAα6 receptor subunit gene(GABRA6)を候補遺伝子とし、SSRIの1つであるfluvoxamine(FLV)による治療反応性との関連について検討した。HAM-Dで14点以上を示した未治療の大うつ病患者113例を対象とした。今回選択した候補遺伝子とFLV反応性との関連は認めなかった。
-
統合失調症の分子病態の解明と新たな診断・治療法の開発 平成18年度 総括研究報告書, 2007
-
依存性薬物および未規制薬物による神経毒性と精神病の発現機序 平成18年度 総括研究報告書 平成16-18年度 総合研究報告書, 2007
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 103 22P-22P, 2007
-
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 141B(7) 707-707, Oct, 2006
-
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 141B(7) 806-807, Oct, 2006
-
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 141B(7) 807-807, Oct, 2006
-
脳と精神の医学, 17(3) 267-272, Sep, 2006統合失調症患者95名の8週間にわたる抗精神病薬治療(リスペリドン単剤)における、陽性陰性評価尺度による不安抑うつ症状の出現とセロトニン4受容体遺伝子(HTR4)多型との関連を検討した。臨床的背景も独立変数に加えた重回帰分析を行った結果、HTR4 508-36T>C多型のTアレルが8週間の抗精神病薬治療における不安抑うつ悪化の予測因子となり、精神病後抑うつの発症に関連することが示唆された。
-
精神科, 9(1) 89-95, Jul, 2006抑うつや幻聴といった精神症状が主体なため身体科では診断が見逃されたあとに精神科に紹介された正常圧水頭症の2例を経験した.症例1(74歳男).実行機能障害の結果として不安・焦燥感・抑うつ気分が生じていることから,大うつ病性障害は認知機能障害を背景にして併発していたと考えられる.はじめ認知機能障害を呈している原疾患が,アルツハイマー型認知症か正常圧水頭症かの鑑別を考えたが,その後MRI画像所見などを総合的にみて,両者の併発という診断に至った.症例2(88歳男).正常圧水頭症の三徴を呈している場合は,精神病像がメインのようにみえても,積極的に画像診断,タップテストを行って鑑別診断をするのが重要であった
-
精神薬療研究年報, (38) 65-69, Mar, 2006損害回避(HA)が遺伝要因で規定されていれば,Temperament and Character Inventory(TCI)によって測定されるHA値の裏付けとして関連遺伝子座位の遺伝子型を組み合わせることにより精度の高い治療反応予測法が開発できるか検討した.自記式の人格検査であるTCIを測定した大うつ病性障害患者98例を対象とし,fluvoxamine単剤加療を8週間行い反応性を検討した.今回検討した遺伝子であるFKBP5,CRHR1,Sigma-1,NRG1での予測因子は認めなかった
-
精神薬療研究年報, (38) 70-75, Mar, 2006AKT1遺伝子およびD1受容体遺伝子(DRD1),D5受容体遺伝子(DRD5)に存在するSNPsがrisperoidone(RIS)の臨床的効果を予測できる可能性について,非遺伝的要因も含めた検討を行った.8週間RIS単剤投与を行い,投与前後で陽性陰性症状評価尺度(PANSS)の改善率を求めた.AKT1,DRD1,DRD5の各遺伝子型とRIS投与によるPANSS改善率との関連を,非遺伝的要因を考慮して,重回帰分析にて解析し,すべてのSNPsはRISによる治療反応性と関連は認めなかった.検討した遺伝子はRIS治療反応性を予測する因子としては有用でないことが示唆された
Books and Other Publications
6Research Projects
16-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2016 - Mar, 2019
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2013 - Mar, 2016
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, 2010 - 2012




